EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL

EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL

Introduction: We report the full analysis of the COMMANDS trial assessing efficacy and safety of luspatercept versus epoetin alfa (EA) in ESA-naive patients with LR-MDS. Methods: 363 patients (aged ≥18 y, with transfusion-dependent LR-MDS, serum erythropoietin <500 U/L) were randomized 1:1 to lus...

Full description

Bibliographic Details
Main Authors: G. Garcia-Manero, U. Platzbecker, V. Santini, A. Zeidan, P. Fenaux, R. Komrokji, J. Shortt, D. Valcarcel, A. Jonasova, S. Dimicoli-Salazar, I.S. Tiong, C.-C. Lin, J. Li, J. Zhang, A.C. Giuseppi, S. Kreitz, V. Pozharskaya, K. Keeperman, S. Rose, T. Prebet, A. Degulys, S. Paolini, T. Cluzeau, M. Della Porta
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Leukemia Research Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048924000372

Internet

http://www.sciencedirect.com/science/article/pii/S2213048924000372

Similar Items